Compare Amgen, Inc. (AMGN) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Cronos Group Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Cronos Group Inc trades at $2.76 (market cap $1.02B). The key difference: Amgen, Inc. is far larger — about 192.3× Cronos Group Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| AMGN | CRON | |
|---|---|---|
Market Cap | $196.12B | $1.02B |
Sector | Health | Health |
52-Week High | $388.16 | $3.27 |
52-Week Low | $271.18 | $1.95 |
Enterprise Value | $241.41B | $200.66M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CRON trades at $2.75, down 1.08% today. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators are neutral. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent Q1 2026 earnings met expectations with $0.01 EPS, and the company expanded its Spinach brand and international footprint.
Outlook is mixed; strong revenue growth and market share gains in Canada and Israel offer upside, but profitability challenges and intense cannabis competition pose risks. Analyst consensus is cautious with 60% hold ratings. Key catalysts include continued international expansion and execution on cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
